Companies in #Oncology (FGFR-driven cancers)
Found 1 company operating in this sector.
BridgeBio Pharma is a clinical-stage biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company's pipeline includes infigratinib (FGFR-driven cholangiocarcinoma and other indications), acoramidis (ATTR-CM, approved 2024), and an achondroplasia therapy that has shown compelling growth and body-proportionality benefit in clinical data.